PROTHENA CORPORATION PLC - ORDINARY SHARES

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

05 Apr 2024 09:45:33 By NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

04 Apr 2024 12:49:03 By NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

03 Apr 2024 09:45:03 By NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

02 Apr 2024 10:53:49 By NetDania Notify

NetDania - New 12 months Low: PROTHENA CORPORATION PLC - ORDINARY SHARES

28 Mar 2024 10:42:06 By NetDania Notify

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

27 Oct 2022 16:05:01 By Nasdaq GlobeNewswire

Prothena to Participate in Upcoming Healthcare Conferences

01 Sep 2022 16:20:00 By Nasdaq GlobeNewswire

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

01 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

08 Aug 2022 16:05:02 By Nasdaq GlobeNewswire

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Prothena to Report Second Quarter 2022 Financial Results on August 8th

01 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2022 16:16:52 By Nasdaq GlobeNewswire

Prothena to Participate in Jefferies Healthcare Conference

02 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Prothena Reports First Quarter 2022 Financial Results and Business Highlights

05 May 2022 16:05:05 By Nasdaq GlobeNewswire

Prothena to Report First Quarter 2022 Financial Results on May 5th

28 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

26 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

28 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Prothena to Participate in Stifel 2022 Virtual CNS Days

21 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022

16 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

17 Feb 2022 16:05:01 By Nasdaq GlobeNewswire